News - CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
BioNTech wins round in CureVac mRNA patent dispute
4 days ago · CureVac – which is developing mRNA-based vaccines for COVID-19 and influenza with GSK – filed suit in the Düsseldorf Regional Court last year, claiming infringement of five patents. A judgment on...
GSK goes all-in on CureVac’s mRNA vaccines | pharmaphorum
4 days ago · GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
Jan 5, 2024 · Results from the formal interim analysis showed that both vaccine candidates using CureVac's proprietary second-generation mRNA backbone produced meaningful immune responses and favorable...
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To …
2 days ago · Notably, analysts forecast that CureVac will break even (at a free cash flow level) in about 15 months. Essentially, that means the company will either reduce its cash burn, or else require more cash.
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune …
Sep 13, 2024 · In this highly aggressive and challenging cancer indication, preliminary immunogenicity results demonstrate that treatment with CVGBM-only following chemo-radiation therapy successfully induces cancer antigen-specific …
CureVac gains $430M GSK vaccine contract, loses 30% of staff
Jul 3, 2024 · GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a...
CureVac N.V. (CVAC) Latest Stock News & Headlines - Yahoo Finance
Nov 12, 2024 · Get the latest CureVac N.V. (CVAC) stock news and headlines to help you in your trading and investing decisions.
CureVac Announces Positive Data on Joint COVID-19 and Flu …
Jan 6, 2023 · Preliminary data from the modified, monovalent mRNA vaccine candidates CV0501 for COVID-19 and Flu-SV-mRNA for flu are being disclosed today, with final Phase 1 data to be published in due course.
CureVac-News: Aktuelle Nachrichten zur Curevac AG - Handelsblatt
Lesen Sie hier aktuelle News und die neuesten Nachrichten von heute zum Biotechunternehmen CureVac. Insgesamt flossen 2024 fast zwei Milliarden Euro neues Kapital an deutsche …
- Some results have been removed